FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS


Date/App# patent app List of recent Antagonist-related patents
10/09/14
20140303372
 Sulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists patent thumbnailSulfonylpyrazole and sulfonylpyrazoline carboxamidine derivatives as 5-ht6 antagonists
And derivatives thereof, which are antagonists of 5-ht6 receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from parkinson's disease, huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, irritable bowel syndrome, obesity and type-2 diabetes..
10/09/14
20140303222
 Dual-acting imidazole antihypertensive agents patent thumbnailDual-acting imidazole antihypertensive agents
Wherein: ar, r, r2-3, x, and r5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.
10/09/14
20140303211
 Compositions containing opioid antagonists patent thumbnailCompositions containing opioid antagonists
Compositions containing opioid antagonists, particularly alvimopan and its active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits, and methods of making and using same are disclosed. In preferred embodiments, invention provides injectable formulations containing opioid antagonists, particularly alvimopan and its active metabolite, having low solubility that may be readily prepared, are stable during storage, and provide maximum levels of opioid antagonists when administered parenterally, particularly via injection.
10/09/14
20140303186
 Nitrogen-containing fused ring compounds as crth2 antagonists patent thumbnailNitrogen-containing fused ring compounds as crth2 antagonists
The present application relates to nitrogen-containing fused ring compounds shown by general formula (i), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as crth2 antagonist, wherein x1, x2, x3, x4, x5, w, x, y, l1, l2, l3, a, b are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of crth2.. .
10/09/14
20140303144
 Compounds and methods of treating hypertension patent thumbnailCompounds and methods of treating hypertension
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2b antagonists.
10/09/14
20140303127
 New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities patent thumbnailNew cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities
The present invention relates to novel compounds having β2 adrenergic agonist and m3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.. .
10/09/14
20140302061
 Biomarkers for tslp treatment patent thumbnailBiomarkers for tslp treatment
The present invention relates to biomarker responsive to treatment with a tslp antagonist.. .
10/09/14
20140302023
 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging patent thumbnailUse of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
A pharmaceutical composition includes one or more rank/rankl antagonists and a pharmaceutically acceptable carrier. The composition can be used for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof.
10/09/14
20140301982
 Complement antagonists and uses thereof patent thumbnailComplement antagonists and uses thereof
Disclosed are antagonists designed to inhibit or block expression of a mammalian complement such as complement component 6 (c6). The invention has a wide range of uses including use in the preparation of a medicament for the enhancement of nerve regeneration following acute or chronic nerve damage in a mammal.
10/02/14
20140296528
 4-aryl-1-(biarylmethylene) piperidine compounds patent thumbnail4-aryl-1-(biarylmethylene) piperidine compounds
The 4-aryl-1-(biarylmethylene)piperidine compounds are piperadine compounds having a biaryl substituent linked to the nitrogen atom of the piperidine ring by a methylene (—ch2—) group, and an aryl moiety attached to the 4-position of the piperidine ring. The aryl moiety may be a methoxy quinoline group, a 2-oxo quinoline group, or a 2-oxo, 3,4-dihydroxy quinoline group.
10/02/14
20140296517
L-setastine hydrochloride and preparation method thereof
The present invention relates to the field of medicine, and disclosed are an l-setastine hydrochloride and a preparation method therefor. The compound of the present invention has the advantages of stronger histamine hi receptor antagonism and small side effect; the yield of the preparation method is more than 80%, and the product purity is high.
10/02/14
20140296513
Novel therapeutic use of p75 receptor antagonists
The present disclosure relates to the use of a p75 receptor antagonist or its pharmaceutically acceptable salts for the preparation of a medicament for use in the treatment and/or prevention of overactive bladder.. .
10/02/14
20140296482
Method to screen for selective peptides that inhibit the biological activity of calcineurin
The invention relates to the biotechnology sector involving the area of human health. More specifically, the invention is based on the surprising usefulness of peptides lxvpc1, c3 and c4 as efficient selective inhibitors of the calcineurin signalling pathway (cn)-nfat and the phosphate activity of cn.
10/02/14
20140296477
Antagonist peptide of the bond between cd47 and a protein belonging to the thrombospondin family
Antagonist peptide of the bond between cd47 and a protein belonging to the thrombospondin family has the sequence s1 r1-r2-r3-s-q-l-l-k-g-r4-r5-r6 and interacts specifically with the c-terminal end of the tsp, at the site of the bond between the tsp and the cd47 receptor. Interaction between the cd47 receptor and the protein is prevented.
10/02/14
20140296276
Sequestered antagonist formulations
Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the mean cmax of the antagonist after single dose oral administration of the dosage form after tampering to the mean cmax of antagonist after single dose oral administration of an intact dosage form is at least 1.5:1.. .
10/02/14
20140296275
Combinations of an opioid/tlr4 antagonist and an alpha-2-delta ligand for use in the treatment of pain
Disclosed are compositions for treatment of pain comprising, a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking toll-like receptor (tlr4) and the second compound is an alpha-2-delta ligand that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone, naloxone and nalmefene.
10/02/14
20140296274
Treatment of pain using a composition of opioid/toll-like receptor 4 antagonists and dextro enantiomers thereof
This invention relates to the use of a composition comprising opioid/toll-like receptor 4 (tlr4) antagonists and dextro enantiomers thereof for the treatment of pain, where the opioid antagonists treat pain by blocking tlr4. More preferably, the dextro opioid/tlr4 antagonist enantiomer treats pain by blocking tlr4 while not affecting the opioid receptors and therefore avoiding adverse effects associated with blocking the opioid receptors.
10/02/14
20140296273
Method and compositions for treatment or prevention of inflammatory conditions
Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin ii receptor (type 1) antagonist, an angiotensin-converting enzyme (ace) inhibitor, and a non-steroidal anti-inflammatory drug..
10/02/14
20140296249
4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use
Dopamine d3 receptor antagonists and partial agonists are known to modulate the reinforcing and drug-seeking effects induced by cocaine and other abused substances. By introducing functionality into the butylamide linking chain of the 4-phenylpiperazine class of ligands, improved d3 receptor affinity and selectivity, as well as water solubility, is achieved.
10/02/14
20140296212
Substituted phenoxypropylcycloamine derivatives as histamine-3 (h3) receptor ligands
Their use as h3 antagonists/inverse agonists, processes for their preparation, and pharmaceutical compositions thereof.. .
10/02/14
20140296209
Compounds and methods for treatment of hypertension
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2b antagonists.
10/02/14
20140296197
Combinations comprising antimuscarinic agents and beta-adrenergic agonists
Combinations comprising (a) a β2 agonist and (b) an antagonist of m3 muscarinic receptors which is 3(r)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion x, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.. .
10/02/14
20140296196
Nk1 antagonists
Or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by nk1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.. .
10/02/14
20140296165
Use of tight junction antagonists to treat inflammatory bowel disease
The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents.
10/02/14
20140296130
Novel inhibitors of mammalian tight junction opening
The present invention provides novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. Peptide tight junction antagonists.
10/02/14
20140295485
Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis.
10/02/14
20140295484
Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis.
10/02/14
20140294931
Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
Thyroid hormone antagonists and their nanoparticle formulations (nanotetrac™ or nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines.
10/02/14
20140294907
Antagonistic properties of reef fish microflora
Disclosed herein are methods for preventing biofilm formation on a surface. The present disclosure also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom..
10/02/14
20140294902
Novel a4b7 peptide antagonists
The invention relates to disulfide-rich peptide molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (madcam) in vivo, and show high selectivity against α4β1 binding.. .
10/02/14
20140294901
Novel a4b7 peptide dimer antagonists
The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (madcam) in vivo, and show high selectivity against α4β1 binding.. .
10/02/14
20140294866
Uses of myostatin antagonists
The present invention provides methods for treating disorders arising from hypogonadism by administering myostatin antagonists to subjects suffering from such disorders.. .
10/02/14
20140294853
Antagonistic dr3 ligands
The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic dr3 ligands useful for treating inflammatory diseases..
10/02/14
20140294830
Method of combination therapy using an egfr antagonist and anti-c-met antibody
A method of combination therapy for prevention and/or treatment of c-met- and/or egfr-induced diseases including co-administering a pharmaceutically effective amount of an egfr antagonist and a pharmaceutically effective amount of an anti-c-met antibody to a subject in need thereof is provided.. .
10/02/14
20140294824
Antibodies that bind to ox40 and their uses
The present invention relates to antagonist antibodies or fragments thereof that bind to human ox40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human ox40 comprising a heavy chain cdr1 comprising the amino acid sequence of seq id no: 1, and/or a heavy chain cdr2 comprising the amino acid sequence of seq id no: 2, and/or a heavy chain cdr3 comprising the amino acid sequence of seq id no: 3; and/or comprising a light chain cdr1 comprising the amino acid sequence of seq id no: 4, and/or a light chain cdr2 comprising the amino acid sequence of seq id no: 5 and/or a light chain cdr3 comprising the amino acid sequence of seq id no: 6..
10/02/14
20140294816
Combination therapy for the treatment of ocular neovascular disorders
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a pdgf antagonist and a vegf antagonist to the patient. The invention also features a pharmaceutical composition containing a pdgf antagonist and a vegf antagonist for the treatment or prevention of a neovascular disorder..
09/25/14
20140288185
Nicotinic receptor non-competitive modulators
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for use, and their pharmaceutical compositions.. .
09/25/14
20140288169
Nicotinic receptor non-competitive antagonists
The present invention relates to compounds that modulate nicotinic receptors as non-competitive antagonists, methods for their synthesis, methods for their use, and their pharmaceutical compositions.. .
09/25/14
20140288149
Mir-142 and antagonists thereof for treating disease
Methods of treating various conditions using mir-142, mir-142 mimics, and antagonists of mir-142 are provided.. .
09/25/14
20140288139
Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
Compositions and methods are provided that are useful for diagnosing, treating, and monitoring alcohol dependence and disorders, susceptibility to alcohol dependence disorders, as well as drug related dependence and disorders. The methods include treating patients with an antagonist of the serotonin receptor 5-ht3 for such disorders, wherein the patient's serotonin transporter gene slc6a4 is known to have particular genotypes..
09/25/14
20140288138
Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
A method is described for the treatment of systemic diseases in cats. A composition is administered to a cat, where the composition includes a therapeutically effective amount of angiotensin ii receptor 1 (at-1) antagonist (sartan)..
09/25/14
20140288112
8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
Wherein r1, r2, r3, a, and g are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds..
09/25/14
20140288106
Cycloalkane carboxylic acid derivatives as cxcr3 receptor antagonists
That are useful for the preventive or therapeutic treatment of diseases caused by abnormal activation of cxcr3 chemokines. The invention relates furthermore to a process for the preparation of said compounds, to pharmaceutical compositions containing said compounds and to novel intermediates used in the preparation of said compounds..
09/25/14
20140288096
P13 kinase antagonists
The present invention provides novel pi3-kinase antagonists and methods of use thereof.. .
09/25/14
20140288057
Method and composition for treating alzheimer-type dementia
There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (achei) in a patient suffering from an alzheimer type dementia by decreasing concomitant adverse effects by administration of said achei in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase inhibition in the cns of said patient is achieved and alleviation of the symptoms of alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of alzheimer type dementia in combination with an acetylcholinesterase inhibitor (achei) and pharmaceutical compositions comprising (a) a 5ht3 receptor antagonist, a dopamine antagonist, a h1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholinesterase inhibitor are also described..
09/25/14
20140288036
Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Described are steroidal c-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines.
09/25/14
20140286965
Ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
The present invention relates to uses, methods and compositions for treating crescentic glomerulonephritis. More specifically, the present invention relates to a ddr1 antagonist or an inhibitor of ddr1 gene expression for the prevention or the treatment of said disease..
09/25/14
20140286953
Hepcidin, hepcidin antagonists and methods of use
The invention relates to purified, correctly folded hepcidin, antibodies that bind hepcidin, and methods of making and using such materials. Also provide are methods of treated hepcidin-related disorders..
09/25/14
20140286936
Anti-human cxcr4 antibodies
The present invention provides novel antibodies to human cxcr4 with high affinity to the target and the ability to act potently as antagonists. The antibodies disclosed herein bind to a diverse range of epitopes..
09/18/14
20140275497
Methods for making cytokine compositions from tissues using non-centrifugal methods
Apparatus and methods for generating a solution rich in interleukin-1 receptor antagonist from a tissue comprising cytokine-producing cells. The apparatus can include a filter used with a separation system.
09/18/14
20140275232
Small molecule antagonists of bacterial quorum-sensing receptors
A novel small molecule antagonizes two types of acyl homoserine lactone receptors: membrane-bound and cytoplasmic. A focused library of analogs and derivatives of the original antagonist was synthesized.
09/18/14
20140275142
Combinations of opioid/tlr4 antagonist and a cyclooxygenase (cox) inhibitor for use in the treatment of pain
Disclosed are compositions for treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking toll-like receptor 4 (tlr4) and the second compound is a cyclooxygenase (cox) inhibitor that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone.
09/18/14
20140275141
Combinations of opioid/tlr4 antagonists and acetyl-para-aminophenol (apap) for use in the treatment of pain
Disclosed are compositions for the treatment of pain comprising a first compound and a second compound, the first compound is an opioid antagonist that treats pain by blocking toll-like receptor 4 (tlr4) and the second compound is acetyl-para-aminophenol (apap) that enhances the pain treatment effect of the first compound. Examples of opioid antagonist include naltrexone and naloxone, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of neuropathic and nociceptive pain..
09/18/14
20140275133
Mineralocorticoid receptor antagonists
The present invention is directed to compounds of the formula (i) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the formula (i), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the formula (i)..
09/18/14
20140275116
Product and method for treating diarrhea
A method of treating diarrhea in a patient includes administering an h1 receptor antagonist and an h2 receptor antagonist to the patient.. .
09/18/14
20140275105
Crystal of androgen receptor antagonistic compound
[solution] a01-type crystal of monohydrate, a01-type crystal of hydrochloride, a01-type crystal of hydrobromide, and a01-type crystal of methanesulfonate of (2r,5s)-4-(3-chloro-4-cyanophenyl)-n-(2-cyclopropylpyrimidin-5-yl)-2,5-dimethylpiperazine-1-carboxamide, which have certain crystal forms, are provided.. .
09/18/14
20140275102
Solid state forms of 6-[4-[3-((r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl] 2h-pyridazine-3-one hydrochloride
Solid state forms of the compound 6-[4-[3-((r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride (compound 1), processes for preparing the solid state forms, and pharmaceutical compositions thereof, are provided. Compound 1 is a histamine h3 receptor antagonist/inverse agonist.
09/18/14
20140275097
Novel chiral n-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor mediated disorders and chiral synthesis thereof
The present invention relates to novel compounds of formula i and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using n-sp3 protective groups.
09/18/14
20140275074
Heterocyclic derivative having pgd2 receptor antagonist activity
Wherein x1, x2, x3, x4, x5, r5, r6, r7, r8, n, p, q, ring a and ring b are as described in the specification, or a pharmaceutically acceptable salt thereof.. .
09/18/14
20140275050
2,5-disubstituted thiomorpholine orexin receptor antagonists
The present invention is directed to 2,5-disubstituted thiomorpholine amide compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2,5-disubstituted thiomorpholine amide compounds described herein in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.
09/18/14
20140275049
Substituted pyrazole analogs as rar antagonists
The present invention provides compounds of formula i or a pharmaceutical salt thereof; methods of treating osteoarthritis and the pain associated with osteoarthritis using the compounds; and processes for preparing the compounds.. .
09/18/14
20140275017
Cgrp receptor antagonists
(wherein variables a1, a2, a3, ring-b, m, n, j, e1, e2, e3, r5, rpg and y are as described herein), which are useful as antagonists of cgrp receptors, and useful in the treatment or prevention of diseases in which cgrp receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (i) and the use of these compounds and compositions in the prevention or treatment of diseases in which cgrp receptors are involved..
09/18/14
20140275006
Azole derivative
Specifically, the invention provides azole derivatives represented by general formula (i), or pharmaceutically acceptable salts thereof that have an antagonistic action against the arginine-vasopressin (avp) v1b receptor:. .


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.3475

3904

0 - 1 - 83